JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
-0.62 (-0.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close140.71
Bid140.44 x 800
Ask140.99 x 1400
Day's Range140.04 - 141.48
52 Week Range120.11 - 148.99
Avg. Volume6,600,980
Market Cap371.947B
Beta (3Y Monthly)0.73
PE Ratio (TTM)25.96
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.80 (2.90%)
Ex-Dividend Date2019-05-24
1y Target Est149.17
Trade prices are not sourced from all markets
  • 5 Top Stocks to Protect Your Portfolio

    5 Top Stocks to Protect Your Portfolio

    The voices are growing louder that the US economy is starting to sputter. From Morgan Stanley, stock strategist Michael Wilson said last month, “Recent data points suggest US earnings and economic risk is greater than most investors may think,” and the May jobs report, released on June 7, backed him up. The numbers were grim, with only 75,000 new jobs reported for the month, and the previous two months revised down by an equal amount. Other data has shown a slowdown in the services sector, and a nine-year low in manufacturing activity.The data is starting to point towards trouble, but the real problem with protecting your portfolio in a downturn lies in the lagging definition of a recession: two consecutive quarters of negative economic growth. Given that growth data is typically reported one month after the fact, this means that investors will always be 4 to 7 months late in taking protective measures. So, let’s be proactive about this, and take a look at TipRanks’ database to find some reliable stocks for defensive investing. These are not necessarily “classic” defensive stocks; rather, these companies have shown by recent performance that they can deliver profits even in a downturn. Apple, Inc. (AAPL)First on our list today is Apple, partly because these days it seems you just can’t build a portfolio without a tech giant but mostly because Apple has proven both its long-term reliability and its short-term resiliency. For the long term, Apple is up 130% in the last five years, while in the short haul the company recovered well from the Q4 2018 downturn and has already made up more than half the losses from last month’s market swoon.More importantly, Apple has also shown that it can adapt and change. Steve Jobs’ unique vision underlay his company’s growth in the early 2000s, and his death in 2011 prompted fears that his successor, Tim Cook, would not fill his shoes and the company would stagnate. It is fair to say that events of the past three quarters have laid that fear to rest. While Cook is not Jobs, he hasn’t needed to be – he took over a mature company with established niches and a growing customer base. He has shown himself fully capable of meeting the challenges the market has posed.Cook met last year’s market dip head-on. He admitted that Apple’s core iPhone sales were not going to fully recover, and orchestrated a plan to meet the changing conditions by shifting the sales focus to Services, reconciling iPhone to a longer replacement cycle, and promoting the iPad, iMac, and Macbook lines. Under all of this, helping to ensure success, is the near-billion strong loyal customer base that the company has built over the past decade.So, Apple has the solid foundation that every defensive stock needs. Looking forward, the company made a favorable impression on market analysts earlier this month at the Worldwide Developers Conference. Kathryn Huberty (Track Record & Ratings) of Morgan Stanley said after Apple’s presentation, “After (Monday’s) announcements, we believe Apple Watch and Mac will more meaningfully contribute to App Store growth, while further solidifying Apple as the most attractive platform for app developers.” Noting the company’s commitment to increasing its Services sector, she added, “Apple's top growth opportunity is driving increased user engagement with apps.” Huberty gives Apple a buy rating with a $231 price target, seeing an upside of 19%.Piper Jaffray’s Michael Olson (Track Record & Ratings) also gives Apple high ratings. Peering into the future of iPhone, he notes that 20% of current owners are interested in upgrading to 5G, and says, “Interest in 5G will only grow from here, so this is a favorable early sign that 5G is viewed as a key feature… we believe that as long as services revenue continues to perform well, it will tide many investors over until anticipation for 5G iPhones intensifies.” His price target on AAPL, $230, also suggests an 19% upside.The analyst consensus on AAPL shares is a ‘Moderate Buy,’ based on 19 buy ratings, 16 holds, 2 sells given over the last three months. Shares are trading at $192, so the $212 average price target indicates an upside of 10%.View AAPL Price Target & Analyst Ratings Detail Johnson & Johnson (JNJ)This one is a traditional defensive stock, and it has a reputation for being a bit staid, but don’t let that fool you: Johnson & Johnson offers real value, consistently delivering on both dividend and long-term equity growth. Both are markers of a strong defensive play.The company’s current dividend yield is 2.72%, which may seem small, but at current share prices it equates to an annual payout of $3.80. Better than the actual dividend payment, however, is JNJ’s dividend history. The company has been paying, and steadily increasing, its dividend since the early 1970s. This policy of consistently rewarding shareholders provides a steady source of income for investors, and also encourages them to reinvest that income in the company. It’s a win-win policy.As a long-term investment, JNJ has, like Apple, proven its worth. The stock has gained 56% in the last 5 years, and shows a 9% gain over the past 12 months. And also like Apple, JNJ has proven resilient in the face of adversity: last December, the stock took a hard hit from bad press related to the widely reported talcum powder recall, but has since regained most of that loss. In another example of corporate resiliency, JNJ was recently given a buy rating with a $157 price target by five-star analyst Joanne Wuensch (Track Record & Ratings) of BMO Capital, after she reviewed the status of current legal action the company faced in the state of Oklahoma in regard to the opioid abuse epidemic. Wuensch notes that the case will likely be resolved quickly, and points out, “Litigation is a common occurrence in the health care sector that takes significant time to resolve, and often headlines are worse than reality.” Her price target indicates confidence in the stock, and a 12% upside.Johnson & Johnson’s success rests on two separate bases. The first, and most widely recognized, is the company’s array of popular consumer brands. JNJ is the producer of Band-Aids, Listerine, and Tylenol, to name just a few. Consumer products provide a respectable 16.7% of annual revenue (nearly $14 billion), but the real money for JNJ lies in pharmaceuticals. To put it in perspective, two drugs – Remicade and Simponi – account for 11.3% of the company’s total revenues, two-thirds as much as all of the consumer products.Unlike many large-scale drug producers, Johnson & Johnson is not deeply exposed to payment issues with the Medicare and Medicaid systems. This is important for investors, as both programs have reputations for underpaying, and with an election year coming up both programs are likely to become political footballs as candidates promise ever more benefits. This is a key point noted by Terence Flynn (Track Record & Ratings). Writing for Goldman Sachs, Flynn says, “The company has the lowest exposure to Medicare/Medicaid within the group. As a result, the stock will be less impacted by potential drug pricing headlines/policy proposals ahead of the 2020 presidential election.” Flynn sets a price target of $163 for JNJ, suggesting an upside of 16%.JNJ’s consensus rating of ‘Moderate Buy’ is derived from 7 buy and 5 hold reviews. The stock’s $149 average price target and $140 share price equate to an upside potential of 7%.View JNJ Price Target & Analyst Ratings Detail McDonald’s Corporation (MCD)Fast food burgers might not come immediately to mind when you hear the phrase ‘Return on Investment,’ but McDonald’s has been delivering more than just quick eats. The company has gained an impressive 16% so far this year, rising from $176 on January 2 to a closing price of $205 on June 14. Even more impressive, between May 3 and June 3, while the S&P 500 was slipping 6.8%, MCD shares were gaining 1.2%.It’s all part of a steady-growth story going back to May of 2015, when current CEO Steve Easterbrook took over. McD’s had just posted its first sales decline in more than a decade, and the new chief’s mandate was simple: refresh a stale brand. His ‘Turnaround Plan’ got the company back to basics, emphasizing fresher, higher quality ingredients; a streamlined menu; and physical rebuilding efforts in the company’s aging franchise locations. Through it all, McDonald’s has maintained its high dividend; the payout is now $4.64 annually, for a yield of 2.26%.The market’s analysts agree that MCD is on a stable upward path. Writing at BTIG, Peter Saleh (Track Record & Ratings) says, “The company's menu strategy shift has boosted comps. Expect the increased menu focus on bundles and full price items – and away from deep discounts - to drive higher U.S. average check for the next couple of quarters.” Saleh boosted his price target to $220 on MCD, suggesting an upside of 7%.Saleh’s not alone. Weighing in from Merrill Lynch last week, Gregory Francfort (Track Record & Ratings) sees “2Q-4Q same-store sales (including 3.9%-4.2% for the U.S.) looking conservative with more upside potential than downside risk.” Like Saleh, he gives MCD a $220 price target.Overall, MCD has a ‘Moderate Buy’ consensus based on 19 analyst ratings given in the last three months, including 14 buys and 5 holds. The stock sells for $205 as of June 14, and the average price target of $216 indicates an upside potential of 5.5%.View MCD Price Target & Analyst Ratings Detail Lowe’s Companies, Inc. (LOW)If the US economy does turn down to recession, Lowe’s is in an excellent position to take advantage of the changed conditions. The do-it-yourself home improvement supplier operates on the big-box model, using bulk to offer discounts on the products and services that, in bad times, homeowners are more likely to handle as DIY.This puts Lowe’s strength as a defensive play is in its niche – the stores offer products that most people need, at discounts that grow more attractive in a downturn. Home maintenance won’t stop for a recession, and DIY really is a good way to save money. In addition, Lowe’s has maintained its lucrative contractor business.And now we get to the weakness in this stock. Lowe’s is the second largest home improvement superstore, after Home Depot (HD), and the company is having trouble boosting revenues and earnings against its larger competition. LOW shares have been on a roller coaster ride for the last 18 months, although they are up nearly 8% year-to-date. On an operational level, Lowe’s has had difficulty executing online sales strategy and home delivery, and managing inventory control. Both are putting serious drag on the bottom line, and holding down revenue growth.Pushing back is CEO Marvin Ellison, who took over in July of last year. He has marked both online sales and inventory control as key parts of a turnaround effort to improve the company’s sales and revenue growth. Early assessments of Ellison’s success are guardedly optimistic; LOW did beat sales and revenue expectations in its most recent quarterly report, although EPS missed by 8%. As Keith Hughes (Track Record & Ratings), of SunTrust Robinson points out, “The recovery will not be a "quick story", even though we are positive on the re-set of expectations and maintain that the 10% projected earnings growth this year still tops Home Depot's (HD) expected flat growth.” Hughes sets a $120 price target on LOW, suggesting an upside of 20%.UBS analyst Michael Lasser (Track Record & Ratings) also sets a buy rating on LOW, with an upbeat $115 target and 15% upside. He writes, “The risk-reward ration on the stock is attractive.”On consensus, Lowe’s keeps a ‘Strong Buy’ rating, based on the 14 buys and 4 holds given in the past three months. While the company faces headwinds, it holds a strong position in a valuable niche, and is widely perceived as facing its difficulties effectively. Of the stocks in this article, LOW offers the best upside potential, at 16%, based on the $99 share price and $115 average price target.View LOW Price Target & Analyst Ratings Detail Walmart, Inc. (WMT)Like Lowe’s, Walmart gains its defensive-stock status from its business model. The king of brick-and-mortar retailers offers discount customers the ultimate in one-stop shopping, putting everything that consumers could want or need under one roof, from baby diapers to daily groceries to minor car repairs. Really, there’s nothing you can’t get at Walmart and that fact has made it the world’s largest company by revenue and the world’s largest private employer.Walmart’s biggest competition comes from (AMZN), but it is more of a whale and elephant story than a cage match. Each company is dominant in its own domain, and each has faced challenges trying to expand on the other’s territory. Walmart may have found a way to leverage its existing stores for an online advantage – rather than offer home delivery (an area in which Amazon already excels), Walmart offers online purchasers an option to pick up their merchandise at the nearest Walmart location. This is a viable alternative, since according to some estimates everyone in the US lives within 10 miles of a Walmart store.As a defensive play, Walmart’s greatest advantage is the pedestrian nature of its business. Everyone needs the products they offer, and in hard times, Walmart’s famously low prices will simply look more attractive. Writing after WMT reported FY20 Q1 earnings, Raymond James’ Budd Bugatch (Track Record & Ratings) said, “Investors should be most encouraged by the U.S. segment, which showed a 5.5 percent year-over-year increase in operating income to $4.1 billion. The business saw strength from a favorable sales mix while e-commerce margins came in better than management's own expectations.” While he believes the company is on firm footing, his price target, at $110, suggests only a modest 1% upside.Guggenheim’s Robert Drbul (Track Record & Ratings) sums up Walmart’s case quite well in his recent research note: “We believe the business remains quite healthy, with solid physical/digital results in recent quarters… We continue to believe WMT’s resources uniquely position it to successfully evolve in an ever-changing retail environment. While trade concerns/tariffs may create quarter-to-quarter fluctuations, we believe the management team will astutely navigate any changes.” Drbul maintained a $115, which indicates a 5.5% upside from current levels.On average, WMT shares have a price target of $113, which gives an upside of 4.5% from the share price of $109. The analyst consensus of ‘Moderate Buy’ is based on 8 buys, 2 holds, and 1 sell set in the last three months.View WMT Price Target & Analyst Ratings DetailYou can learn more about these stocks using TipRanks Stock Comparison tool. This is a powerful new tool that shows all the data on multiple stocks. See for yourself how the Comparison Tool works, by using it to look at the stocks in this article.Disclosure: This author holds a long position in Apple, Inc.

  • Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
    Zacks3 days ago

    Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion

    Dassault's acquisition of Medidata (MDSO) to close by 2019-end.

  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zacks3 days ago

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

  • The Opioid Epidemic Will Be A Yearslong Overhang For These Pharma Stocks
    Investor's Business Daily4 days ago

    The Opioid Epidemic Will Be A Yearslong Overhang For These Pharma Stocks

    Ongoing litigation surrounding the opioid epidemic will be a yearslong overhang for several pharmaceutical companies like Teva Pharmaceutical, Mylan and Endo, an analyst said Thursday.

  • Barrons.com4 days ago

    Johnson & Johnson Made the Right Call in Fighting Oklahoma Over Opioids, Analyst Says

    Teva Pharmaceutical and Purdue Pharma both settled with Oklahoma over allegations they contributed to the state’s opioid crisis.

  • Market Exclusive4 days ago

    Market Morning: Huawei Strikes Back, ‘No’ on No No Deal, Ancient Chinese Stoners, Crowded CrowdStrike

    Huawei Strikes Back…Against Verizon Chinese Telecom Huawei, pretty upset about President Trump’s sanctions against the company that have led to Alphabet (NASDAQ:GOOGL) banning the company from using its Android operating system for its phones among other things, is striking back by insisting that Verizon (NYSE:VZ) pay it $1 billion in licensing fees for 230 patents […]The post Market Morning: Huawei Strikes Back, 'No' on No No Deal, Ancient Chinese Stoners, Crowded CrowdStrike appeared first on Market Exclusive.

  • Barrons.com4 days ago

    Johnson & Johnson and Cisco Directors Are Buying Up Stock

    Lockheed CEO Marillyn Hewson made the first insider purchase of J&J stock this year, while Northrop Grumman Chairman Wes Bush bought up Cisco stock.

  • TheStreet.com5 days ago

    Jim Cramer: A Tale of Two Stocks

    I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

  • Pharma Giant Nears Two-Decade Low As Opioid Settlement Remains In Limbo
    Investor's Business Daily5 days ago

    Pharma Giant Nears Two-Decade Low As Opioid Settlement Remains In Limbo

    Teva Pharmaceutical skidded to a nearly two-decade low Wednesday amid confusion over its $85 million payment to Oklahoma to settle an ongoing opioid abuse case. J&J remains a defendant.

  • Why This Dow Jones Pharmaceutical Giant Is Trying To Break Out
    Investor's Business Daily5 days ago

    Why This Dow Jones Pharmaceutical Giant Is Trying To Break Out

    Shares of pharmaceutical companies Johnson & Johnson and Novo Nordisk popped Wednesday on bullish expectations for their diabetes treatments after the American Diabetes Association meeting.

  • Teva Retests Lows After Judge Declines Settlement Offer
    Investopedia5 days ago

    Teva Retests Lows After Judge Declines Settlement Offer

    Teva shares briefly reached fresh lows after an Oklahoma judge declined the company's settlement offer and requested more information.

  • Traders Look to Buy Global Health Care Stocks
    Investopedia5 days ago

    Traders Look to Buy Global Health Care Stocks

    The patterns forming on the long-term charts suggest that the global health care sector could be poised for a prolonged move higher.

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks6 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $139.78, moving +0.55% from the previous trading session.

  • 13 Blue-Chip Stocks With Risks You Need to Watch
    Kiplinger6 days ago

    13 Blue-Chip Stocks With Risks You Need to Watch

    Every company faces headwinds at some point. Even the bluest of blue-chip stocks must tackle a serious threat from time to time.Dangers can come from anywhere. They can be industrial accidents such as the 2010 Deepwater Horizon oil spill that cost BP plc (BP) nearly $65 billion in legal fees, settlements and cleanup costs as of 2018. There are technological squabbles, such as Apple's (AAPL) 2017 patent infringement lawsuit settlement with Nokia, which forced the iPhone maker to pay $2 billion upfront as well as ongoing royalties from iPhone sales. Pfizer (PFE) was weighed down considerably in 2011 as it was about to lose market exclusivity on its blockbuster cholesterol drug Lipitor - this so-called patent cliff is a frequent headwind for pharma stocks.Some blue chips, such as Apple and Pfizer, take the hit and keep on chugging. Others, like BP, take much longer to recover - if they ever do.You can get some insight into potential headwinds by reading the "Risk Factors" section of each company's annual 10-K filing. Companies are required to list, by order of importance, the most significant risks challenging future profits or stock performance. Some risks apply to the entire economy, some to that particular industry and a few are unique to that company.Here are 13 blue-chip stocks that currently are navigating their way around a landmine or two. This isn't necessarily a list of stocks to sell, however. Great companies can often overcome major setbacks, and many of these companies are working toward that. But retirees need to be especially aware of forces that threaten substantial shorter-term losses. And even the most ardent bull should acknowledge and understand significant risks - even if they merely set a stock up for a dip-buying situation. SEE ALSO: 20 More Best Stocks to Buy That You Haven't Heard Of

  • Johnson & Johnson Is A Massive Pharma Stock — But Should You Buy It?
    Investor's Business Daily6 days ago

    Johnson & Johnson Is A Massive Pharma Stock — But Should You Buy It?

    JNJ stock broke out in early April. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares. So, is the Dow Jones component a buy right now?

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    Johnson & Johnson NYSE:JNJView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for JNJ with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold JNJ had net inflows of $6.54 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. JNJ credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: ...

  • How Analysts Rate Tandem Diabetes Care and Insulet
    Market Realist7 days ago

    How Analysts Rate Tandem Diabetes Care and Insulet

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson

  • Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May
    Motley Fool7 days ago

    Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May

    The biopharma company started several new clinical trials and enjoyed success in others since the start of the calendar year.

  • Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson
    Motley Fool10 days ago

    Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson

    The case, which is premised on a unproven legal theory, could impact the course of future opioid litigation.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper
    Zacks10 days ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper

  • Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
    Zacks10 days ago

    Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

    Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

  • Barrons.com10 days ago

    Teva and J&J Stocks Were Hit by Opioid Worries. What Could Come Next.

    A federal judge in Ohio is pushing for a settlement that could sweep in more than a thousand separate opioid lawsuits.

  • Should You Be Holding Johnson & Johnson (NYSE:JNJ)?
    Simply Wall St.10 days ago

    Should You Be Holding Johnson & Johnson (NYSE:JNJ)?

    Johnson & Johnson (NYSE:JNJ) is a company with exceptional fundamental characteristics. Upon building up an investment...

  • Barrons.com10 days ago

    How Funds That Chase the Hottest Stocks Can Still Lag Behind

    How often momentum funds adjust their holdings, and when they do so, can make a big difference to their performance. A rebalancing in May came at just the wrong time for one momentum ETF.